Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. (February 2014)

• Record Type: Journal Article
• Authors: Saraceno, Rosita; Camplone, Germana; D'Agostino, Magda; De Simone, Clara; Di Cesare, Antonella; Filosa, Giorgio; Frascione, Pasquale; Gabellini, Massimo; Lunghi, Franco; Mazzotta, Annamaria; Peris, Ketty; Scotto Di Luzio, Genoveffa; Calvieri, Stefano; Simonacci, Marco; Chimenti, Sergio
• Is Part Of: Journal of dermatological treatment. Volume 25:Number 1(2014:Feb.)
• Page Start: 30
• Page End: 33
• Publication Date: 2014-02
• Subjects: Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.3109/09546634.2013.800182
• Languages: English
• ISSNs: 0954-6634

Abstract

<abstract> <title /> <p> <italic>Background:</italic> Previous studies showed the efficacy of a formulation containing calcipotriol and betamethasone dipropionate for the treatment of psoriasis. <italic>Objective:</italic> To investigate maintenance strategies of a formulation containing calcipotriol (50 µg/g) and betamethasone dipropionate (0.5 mg/g) for the treatment of scalp psoriasis. <italic>Materials and methods:</italic> Nine-hundred and four patients were screened and randomised on a 1:1 basis in two groups: maintenance of two applications per week (group A) versus on-demand therapy (group B). Clinical evaluation was performed at weeks 0, 2, 4, 8 and 12. <italic>Results:</italic> Eight-hundred and eighty-five patients were randomised: 441 in group A and 444 in group B. From week 2, both groups showed a significant clinical improvement compared with baseline; at weeks 8 and 12, group A demonstrated a higher clinical response compared with group B (<italic>p</italic> &lt; 0.05). This difference was statistically significant (OR 0.47, 95% CI 0.37, 0.60). <italic>Conclusions:</italic> The maintenance of twice-weekly application versus on-demand treatment of calcipotriol/betamethasone dipropionate gel is more effective and is associated with a lower rate of relapse.</p> </abstract>